Idelalisib for the treatment of chronic lymphocytic leukemia

about

DNA damage response and evasion from immunosurveillance in CLL: new options for NK cell-based immunotherapies.

P2860

Q39037081-384355DA-3056-4573-B42C-D71E2380911F

P2860

Idelalisib for the treatment of chronic lymphocytic leukemia

Item

http://www.wikidata.org/entity/Q27015826

description

2014 nî lūn-bûn

@nan

2014 թուականին հրատարակուած գիտական յօդուած

@hyw

2014 թվականին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Idelalisib for the treatment of chronic lymphocytic leukemia

@ast

Idelalisib for the treatment of chronic lymphocytic leukemia

@en

Idelalisib for the treatment of chronic lymphocytic leukemia

@nl

type

Item

label

Idelalisib for the treatment of chronic lymphocytic leukemia

@ast

Idelalisib for the treatment of chronic lymphocytic leukemia

@en

Idelalisib for the treatment of chronic lymphocytic leukemia

@nl

prefLabel

Idelalisib for the treatment of chronic lymphocytic leukemia

@ast

Idelalisib for the treatment of chronic lymphocytic leukemia

@en

Idelalisib for the treatment of chronic lymphocytic leukemia

@nl

P1476

Idelalisib for the treatment of chronic lymphocytic leukemia

@en

P2093

Maliha Khan

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

B-cell adaptor for PI3K (BCAP) negatively regulates Toll-like receptor signaling through activation of PI3K

Role for B-cell adapter for PI3K (BCAP) as a signaling adapter linking Toll-like receptors (TLRs) to serine/threonine kinases PI3K/Akt

The emerging mechanisms of isoform-specific PI3K signalling

Autoimmune cytopenias in chronic lymphocytic leukemia, facts and myths

A positive regulatory role for Cbl family proteins in tumor necrosis factor-related activation-induced cytokine (trance) and CD40L-mediated Akt activation.

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.

B-cell receptor signaling as a driver of lymphoma development and evolution.

P304

931858

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2014/931858

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

2014

http://www.w3.org/2001/XMLSchema#string

P50

Aibek E Mirrakhimov

Areeba Saif

Steven Sandler

P577

2014-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264539673

http://www.w3.org/2001/XMLSchema#string

P698

25093123

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

idelalisib

lymphocyte

P932

4003830

http://www.w3.org/2001/XMLSchema#string

Idelalisib for the treatment of chronic lymphocytic leukemia

about

P2860

P2860

Idelalisib for the treatment of chronic lymphocytic leukemia

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P5875

P698

P921

P932